TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being sold across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease, has successfully concluded a Phase IIa trial in rheumatoid arthritis, as well as a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
22 April 2013 - TiGenix reports positive Phase IIa study results in refractory rheumatoid arthritis with allogeneic stem cell product Cx611 (archived call under MP3) (EN - NL - FR) - Presentation - MP3
World Stem Cell and Regenerative Medicine Congress, Victoria Plaza, London, UK
May 21-23, 2013
BioEquity Europe, Stockholm, Sweden
May 22-23, 2013
Knowledge for Growth, ICC Ghent, Belgium
May 30, 2013